Insider Transactions in Q4 2023 at Immunovant, Inc. (IMVT)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2023
|
Andrew J. Fromkin Director |
SELL
Open market or private sale
|
Direct |
12,350
-4.25%
|
$481,650
$39.68 P/Share
|
|
Dec 01
2023
|
George V Migausky Director |
SELL
Open market or private sale
|
Direct |
12,700
-3.58%
|
$495,300
$39.69 P/Share
|
|
Dec 01
2023
|
Atul Pande Director |
SELL
Open market or private sale
|
Direct |
12,350
-4.51%
|
$481,650
$39.69 P/Share
|
|
Nov 22
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,217
-0.84%
|
$535,161
$33.14 P/Share
|
|
Nov 22
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,055
-0.61%
|
$133,815
$33.14 P/Share
|
|
Nov 22
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,265
-0.48%
|
$107,745
$33.14 P/Share
|
|
Nov 22
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,265
-0.39%
|
$107,745
$33.14 P/Share
|
|
Nov 22
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,252
-0.52%
|
$107,316
$33.14 P/Share
|
|
Oct 25
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,107
-1.31%
|
$139,638
$34.66 P/Share
|
|
Oct 19
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
530
-0.16%
|
$19,080
$36.8 P/Share
|
|
Oct 10
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,557
-1.36%
|
$164,052
$36.92 P/Share
|
|
Oct 05
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,735
-0.21%
|
$60,725
$35.97 P/Share
|
|
Oct 05
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,239
-0.27%
|
$183,365
$35.97 P/Share
|
|
Oct 02
2023
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
1,526,316
+1.88%
|
$58,000,008
$38.0 P/Share
|
|
Oct 02
2023
|
Roivant Sciences Ltd. |
BUY
Grant, award, or other acquisition
|
Direct |
4,473,684
+5.41%
|
$169,999,992
$38.0 P/Share
|